MKGAF Stock UPDATES Merck Kgaa Dm 5 (MKGAF) 85.3000 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck Kgaa Dm 5 (MKGAF) 85.3000 $MKGAF

Merck KGaA Q2 Earnings Slip Y/Y, 2014 Sales View Confirmed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 8:00AM CDT
Merck KGaA's (MKGAF) second-quarter 2014 earnings per American Depositary Receipt (ADR) came in at $1.52, down 1.8% from the year-ago quarter.

Roche Collaborates with Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 5:30PM CDT
Roche's (RHHBY) Ventana Medical Systems announced that it has entered into an agreement with Germany-based Merck KGaA.

Merck KGaA-Mersana Therapeutics Strike a Deal on ADCs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 4:20PM CDT
Merck KGaA (MKGAF) inked a deal with Mersana Therapeutics for the development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancer.

Merck KGaA-Ono Pharma Deal Ends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 5:15PM CDT
Merck KGaA (MKGAF) has decided to terminate its license agreement with Ono Pharma related to the development of Ono Pharma's multiple sclerosis candidate, ceralifimod (ONO-4641).

Merck KGaA & MorphoSys Sign Deal, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 3:30PM CDT
Merck KGaA (MKGAF) and MorphoSys inked a deal to discover and develop therapeutic antibodies against undisclosed immune checkpoints.

Merck KGaA/Auxogyn's Eeva System Gets FDA Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 3:40PM CDT
Merck KGaA's (MKGAF) biopharma division, Merck Serono, announced that the FDA has granted clearance to Merck KGaA and partner Auxogyn's Early Embryo Viability Assessment (Eeva) System.

Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris

Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.

Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents

Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.

Avanir Reports Wider Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 11, 8:37AM CST
Avanir reported 4Q13 net loss per share of 10 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents

Threshold Pharma's TH-302 in Melanoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 12:00PM CDT
Threshold Pharmaceuticals recently initiated a phase II trial on its pipeline candidate, TH-302.

Update on Threshold Pharma's TH-302 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 08, 10:20PM CDT
Threshold Pharma announced an amendment in the protocol for its pivotal phase III study of TH-302

Sanofi's Lemtrada Gets CHMP Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 01, 11:40AM CDT
The Committee for Medicinal Products for Human Use recommended the approval of Lemtrada

Data on Merck KGaA's L-BLP25 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 22, 9:00PM CDT
Merck KGaA presented detailed results on its oncology candidate L-BLP25, from the phase III study, START.

Merck KGaA Posts Higher Y/Y Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 15, 10:24AM CDT
Merck KGaA reported first quarter 2013 earnings per American Depository Receipt (ADR) of $2.79, up 28.1% year over year.

Merck KGaA-CBRX Renew Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 11, 3:00PM CDT
Merck KGaA and Columbia Labs renewed a license and supply agreement for Crinone (progesterone gel), extending it for an additional five years

Sanofi Reports Lemtrada Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 27, 4:30PM CDT
Sanofi's subsidiary, Genzyme, announced interim data on Lemtrada.

Merck KGaA-BMY Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 21, 4:15PM CDT
Merck KGaA announced a deal with Bristol-Myers Squibb for the promotion of different formulations of Glucophage (metformin hydrochloride) in China.

Merck KGaA - Nordic Bioscience Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 20, 4:00PM CDT
Merck KGaA recently announced a strategic deal with Nordic Bioscience Clinical Development A/S for its pipeline candidate, sprifermin.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 4

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 7

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 4

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 7

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 7

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 0

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 5

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 3

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 3

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Auto Loan Preapproval for Smart Buying

Updated Category News Views 8

A Fresh Perspective on Auto Loan Preapproval Diving into the maze of auto financing, sometimes you gotta stop and smell the coffee—that's where this HelloNation piece comes in, serving a dose of clarity for potential car buyers. Brad Bailey, the top dog at Red River Credit Union, steps into the fray to break it down. Gaining Financial Insight Ahead of the Game Think of...

Continue Reading
ArcelorMittal's Vision for Decarbonization in Europe Highlights

Updated Category News Views 147

ArcelorMittal's Commitment to Decarbonization ArcelorMittal is on a transformative journey to reshape its decarbonization strategy in Europe. The company has laid out a roadmap that prioritizes the replacement of traditional blast furnaces with lower carbon emissions facilities, specifically hydrogen-ready DRI-EAF systems. This endeavor marks a pivotal step forward in...

Continue Reading
Will International Stocks Outperform U.S. Markets This Year?

Updated Category News Views 193

Can International Stocks Surpass U.S. Performance? According to recent insights from a Vanguard economist, the landscape for stock investments is shifting, suggesting that international markets might finally outpace U.S. stocks. After facing challenges early in the year, U.S. stocks have rebounded impressively. The S&P 500 index has increased by approximately 16%...

Continue Reading
MellingMedical Secures Federal Supply Schedule for Pharmaceuticals

Updated Category News Views 216

MellingMedical Receives Federal Supply Schedule Contract MellingMedical proudly announces its successful acquisition of a federal contract specifically designed for essential pharmaceuticals. This new agreement plays a pivotal role in ensuring America's veterans have timely access to critical medications and health products. Understanding the Federal Supply Schedule The...

Continue Reading
GBM Gains Edge with Dr. Paik's Strategic Appointment

Updated Category News Views 9

A Heavyweight Joins the Global Battery Materials Camp This isn't your run-of-the-mill executive shuffle, folks. Global Battery Materials Corp. (GBM) has just brought in a marksman in the battery world—Dr. Yi Hyon Paik. The guy doesn't just dabble; he's chalked up over 30 years in the trenches of battery technology, electronic materials, and the big leagues of energy...

Continue Reading